We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+16.8%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.5B
AUM Growth
+$164M
Cap. Flow
-$95.8M
Cap. Flow %
-3.83%
Top 10 Hldgs %
71.22%
Holding
36
New
–
Increased
18
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$49.5M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$16.2M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$5.91M
4
SAGE
Sage Therapeutics
SAGE
+$2.23M
5
INSM icon
Insmed
INSM
+$1.98M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$165M
2
ALGN icon
Align Technology
ALGN
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
1
DELISTED
Abiomed Inc
ABMD
$364M 14.55%
890,309
-456,351
-34% -$165M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$12.4B
$240M 9.6%
2,549,431
+3,949
+0.2% +$346K
CLVS
3
DELISTED
Clovis Oncology, Inc.
CLVS
$226M 9.04%
4,974,007
+1,018,347
+26% +$49.5M
UTHR icon
4
United Therapeutics
UTHR
$23.1B
$184M 7.35%
1,625,234
+2,603
+0.2% +$286K
INSM icon
5
Insmed
INSM
$28.6B
$171M 6.84%
7,236,583
+76,993
+1% +$1.98M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$147M 5.89%
1,186,427
+50,582
+4% +$5.91M
SAGE
7
DELISTED
Sage Therapeutics
SAGE
$130M 5.21%
832,536
+14,205
+2% +$2.23M
IMMU
8
DELISTED
Immunomedics Inc
IMMU
$114M 4.54%
4,803,364
+7,356
+0.2% +$148K
STAA icon
9
STAAR Surgical
STAA
$1.21B
$109M 4.36%
3,521,565
+6,180
+0.2% +$145K
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$96.3M 3.85%
6,168,347
+20,518
+0.3% +$310K
EPZM
11
DELISTED
Epizyme, Inc
EPZM
$93.6M 3.74%
6,906,158
+11,083
+0.2% +$172K
KPTI icon
12
Karyopharm Therapeutics
KPTI
$48M
$79.2M 3.17%
310,888
+65,556
+27% +$16.2M
VNDA icon
13
Vanda Pharmaceuticals
VNDA
$302M
$79.2M 3.16%
4,155,670
– –
WMGI
14
DELISTED
Wright Medical Group Inc
WMGI
$71.6M 2.86%
2,757,587
+5,293
+0.2% +$121K
AMAG
15
DELISTED
AMAG Pharmaceuticals
AMAG
$65.1M 2.6%
3,340,806
– –
ALGN icon
16
Align Technology
ALGN
$12.3B
$63.2M 2.52%
184,607
-34,100
-16% -$10.2M
MNTA
17
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$37.5M 1.5%
1,833,532
+3,097
+0.2% +$66.5K
AIMT
18
DELISTED
Aimmune Therapeutics
AIMT
$37.2M 1.48%
1,381,759
+25,245
+2% +$773K
SHPG
19
DELISTED
Shire pic
SHPG
$32.3M 1.29%
191,200
– –
CELG
20
DELISTED
Celgene Corp
CELG
$31.4M 1.25%
394,840
+15,700
+4% +$1.3M
ALDR
21
DELISTED
Alder Biopharmaceuticals
ALDR
$29.3M 1.17%
1,853,101
+3,269
+0.2% +$49.7K
ACAD icon
22
Acadia Pharmaceuticals
ACAD
$5.03B
$25.2M 1.01%
1,650,780
– –
EXAS
23
DELISTED
Exact Sciences
EXAS
$18.7M 0.75%
313,320
+601
+0.2% +$32.3K
PRTA icon
24
Prothena Corp
PRTA
$450M
$16.1M 0.64%
1,103,325
+1,987
+0.2% +$39.3K
GILD icon
25
Gilead Sciences
GILD
$165B
$12.5M 0.5%
175,900
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q2 2018 Portfolio in Review

As of Q2 2018, Palo Alto Investors held 36 positions worth $2.5B, up 7% from $2.34B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Palo Alto Investors withdrew a net $95.8M in Q2 2018, reducing 2 holdings. Its largest reduction was Abiomed Inc, cutting an estimated $165M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier.

Against the trend, Palo Alto Investors added an estimated $49.5M to Clovis Oncology, Inc..

  • Palo Alto Investors added most to Clovis Oncology, Inc. in Q2 2018, an estimated $49.5M increase.
  • Palo Alto Investors's biggest Q2 2018 reduction was Abiomed Inc, cutting an estimated $165M.
  • Palo Alto Investors's ten largest holdings make up 71% of its $2.5B portfolio in Q2 2018.
  • Palo Alto Investors opened 0 new positions and closed 0 in Q2 2018.
  • Palo Alto Investors's portfolio value rose 7% quarter-over-quarter to $2.5B.

Based on Palo Alto Investors's 13F filing for Q2 2018, filed 14 Aug 2018.